{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:15:31Z","timestamp":1775898931723,"version":"3.50.1"},"reference-count":29,"publisher":"The Journal of Rheumatology","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,5,7]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>There is a key knowledge gap in quantifying residual disease activity in Canadian patients with axial spondyloarthritis (axSpA). The objective of this study was to evaluate and describe residual disease activity and burden of disease in Canadian patients with axSpA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was an observational, retrospective analysis of data extracted from the Rhumadata (Qu\u00e9bec), Spondyloarthritis Research Consortium of Canada (SPARCC; East\/Atlantic and West regions, as well as Ontario), and Follow-up Research Cohort of Ankylosing Spondylitis (FORCAST; Alberta) registries. The primary endpoint was the proportion of patients who failed to achieve sustained low disease activity (LDA) at 12 months. LDA was defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score &lt; 3 and sustained LDA was defined as achieving LDA at both 6 and 12 months after the most recent change in treatment. Analyses included outcomes by treatment class (nonsteroidal antiinflammatory drugs, tumor necrosis factor inhibitor, or interleukin 17 inhibitor).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 980 patients (Rhumadata, N = 488; SPARCC, N = 239; FORCAST, N = 253) were included. Nearly half of patients with axSpA from Rhumadata (49.5%) and FORCAST (55.3%) and 65.8% of those from SPARCC failed to achieve LDA (BASDAI &lt; 3) at 6 months after treatment initiation. At 12 months, failure to achieve sustained LDA rose to 62% in Rhumadata, 65.1% in FORCAST, and 81% in SPARCC. Pain persisted in nearly half of all patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This analysis demonstrated that most Canadians with axSpA failed to achieve sustained LDA after 12 months of initiating their latest therapy and confirms a high unmet need for additional treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2024-1303","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:35:22Z","timestamp":1751358922000},"page":"1089-1097","source":"Crossref","is-referenced-by-count":3,"title":["Residual Disease Activity and Burden of Disease in Canadian Patients With Axial Spondyloarthritis: Results From a Multiregistry Analysis (UNISON-Axial SpA)"],"prefix":"10.3899","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6585-7695","authenticated-orcid":false,"given":"Denis","family":"Choquette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4750-1422","authenticated-orcid":false,"given":"Robert D.","family":"Inman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-2029","authenticated-orcid":false,"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0178-1331","authenticated-orcid":false,"given":"Marie-Claude","family":"Lalibert\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Andr\u00e9","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Girard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4170-1244","authenticated-orcid":false,"given":"Stephanie","family":"Wichuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0828-9665","authenticated-orcid":false,"given":"Louis","family":"Coupal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-0275","authenticated-orcid":false,"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8949-4198","authenticated-orcid":false,"given":"Sherry","family":"Rohekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4259-9002","authenticated-orcid":false,"given":"Tristan","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9296-2842","authenticated-orcid":false,"given":"Michel","family":"Zummer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3683-8713","authenticated-orcid":false,"given":"Nicolas","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1721-190X","authenticated-orcid":false,"given":"Carter","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7324-8459","authenticated-orcid":false,"given":"Dianne","family":"Mosher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Ziouzina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1620-5022","authenticated-orcid":false,"given":"Alexander","family":"Tsoukas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Starr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1837-5340","authenticated-orcid":false,"given":"Jonathan","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8792-4449","authenticated-orcid":false,"given":"Sibel Zehra","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-1755","authenticated-orcid":false,"given":"Walter P.","family":"Maksymowych","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2025120301250851000_52.11.1089.1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24025"},{"key":"2025120301250851000_52.11.1089.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406182"},{"key":"2025120301250851000_52.11.1089.3","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000475"},{"key":"2025120301250851000_52.11.1089.4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/acr.22959","article-title":"Inflammatory arthritis prevalence and health services use in the First Nations and non-First Nations populations of Alberta, Canada","volume":"69","author":"Barnabe","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2025120301250851000_52.11.1089.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"2025120301250851000_52.11.1089.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102398"},{"key":"2025120301250851000_52.11.1089.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296"},{"key":"2025120301250851000_52.11.1089.8","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-020-00442-x"},{"key":"2025120301250851000_52.11.1089.9","doi-asserted-by":"publisher","DOI":"10.1097\/01.j.pain.0000460310.71572.16"},{"key":"2025120301250851000_52.11.1089.10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40744-019-0160-8","article-title":"Insight into the quality of life of patients with ankylosing spondylitis: real-world data from a US-based life impact survey","volume":"6","author":"Rosenbaum","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2025120301250851000_52.11.1089.11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13075-023-03055-1","article-title":"Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?","volume":"25","author":"Maksymowych","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"2025120301250851000_52.11.1089.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.23527"},{"key":"2025120301250851000_52.11.1089.13","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/acr.20131","article-title":"Thresholds of patient-reported outcomes that define the patient acceptable symptom state in ankylosing spondylitis vary over time and by treatment and patient characteristics","volume":"62","author":"Maksymowych","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2025120301250851000_52.11.1089.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.22469"},{"key":"2025120301250851000_52.11.1089.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222747"},{"key":"2025120301250851000_52.11.1089.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094870"},{"key":"2025120301250851000_52.11.1089.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104018"},{"key":"2025120301250851000_52.11.1089.18","first-page":"1079","article-title":"Development of a core set of domains for data collection in cohorts of patients with ankylosing spondylitis receiving Anti-tumor necrosis factor-alpha therapy","volume":"35","author":"Zochling","year":"2008","journal-title":"J Rheumatol"},{"key":"2025120301250851000_52.11.1089.19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11926-015-0522-3","article-title":"Clinical tools to assess and monitor spondyloarthritis","volume":"17","author":"Landew\u00e9","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"2025120301250851000_52.11.1089.20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151244"},{"key":"2025120301250851000_52.11.1089.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213184"},{"key":"2025120301250851000_52.11.1089.22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab901"},{"key":"2025120301250851000_52.11.1089.23","unstructured":"Arthritis Society Canada . Ankylosing spondylitis. [Internet. Accessed June 26, 2025.] Available from: https:\/\/arthritis.ca\/about-arthritis\/arthritis-types-(a-z)\/types\/ankylosing-spondylitis#:~:text=How%20common%20is%20ankylosing%20spondylitis,(300%2C000)%20lives%20with%20AS"},{"key":"2025120301250851000_52.11.1089.24","first-page":"289","article-title":"Costs and quality of life of patients with ankylosing spondylitis in Canada","volume":"33","author":"Kobelt","year":"2006","journal-title":"J Rheumatol"},{"key":"2025120301250851000_52.11.1089.25","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170222"},{"key":"2025120301250851000_52.11.1089.26","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23465"},{"key":"2025120301250851000_52.11.1089.27","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.5001\/omj.2022.69","article-title":"Predictors of not achieving remission or low disease activity in axial spondyloarthritis patients from Middle Eastern countries: A prospective, multicenter, real-world study","volume":"37","author":"Al-Saleh","year":"2022","journal-title":"Oman Med J"},{"key":"2025120301250851000_52.11.1089.28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-057850"},{"key":"2025120301250851000_52.11.1089.29","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.3390\/jcm11123553","article-title":"Residual disease in patients with axial spondyloarthritis: a post-hoc analysis of the QUASAR study","volume":"11","author":"D\u2019Angelo","year":"2022","journal-title":"J Clin Med"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2024-1303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T09:25:49Z","timestamp":1764753949000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2024-1303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,1]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.3899\/jrheum.2024-1303"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2024-1303","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}